Champions Oncology(NASDAQ) CSBR

Market Cap$74.47M

Since IPO (1992)-55%

5 Year-49%

1 Year-15%

1 Month-11%

$5.22

-4.40%

-0.24Today

After hours$5.44+$0.22 (+4.22%)

Champions Oncology last closing stock price
Metric	Price	Date
Last close	USD 5.36	2026-07-31

Champions Oncology stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-12.56%	USD 6.13	2026-07-24
1 month	-11.33%	USD 6.05	2026-07-01
3 month	-10.52%	USD 5.99	2026-05-01
Year to date	-22.43%	USD 6.91	2025-12-31
1 year	-15.19%	USD 6.32	2025-07-31
3 year	-15.59%	USD 6.35	2023-08-01
5 year	-48.71%	USD 10.45	2021-07-30
Since inception	-55.33%	USD 12.00	1992-05-01

Champions Oncology Financials at a Glance

Market Cap

$74.47M

Revenue (TTM)

$59.43M

Net Income (TTM)

-$1.18M

EPS (TTM)

-$0.08

P/E Ratio

-66.01

Dividend

$0.00

Beta (Volatility)

0.36 (Low)

Dividend

$0.00

Beta (Volatility)

0.36 (Low)

Price

$5.22

Volume

2,005.346

Open

$5.32

Price

$5.22

Volume

2,005.346

Open

$5.32

Previous Close

$5.36

Daily Range

$5.32 - $5.50

52-Week Range

$5.22 - $8.74

Estimated Earnings Date

Sep 14, 2026

Dividend

$0.00

Beta (Volatility)

0.36 (Low)

Price

$5.22

Volume

2,005.346

Open

$5.32

Previous Close

$5.36

Daily Range

$5.32 - $5.50

52-Week Range

$5.22 - $8.74

Estimated Earnings Date

Sep 14, 2026

CSBR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Champions Oncology

Champions Oncology is a technology-driven research organization focused on drug discovery and development. Their technology assists pharmaceutical companies in creating more effective cancer therapies.

The Cancer-Fighting Toolkit

Translational Oncology Solutions: Provides pharmaceutical and biotech companies with drug development support through computational and experimental research platforms.

Evolution of a Cancer Tech Pioneer

Headquartered in Hackensack, New Jersey.

What Sets Champions Apart

Their integrated research platforms combine computational and experimental approaches to advance drug development.

Financial Vital Signs

Total revenue reached $44.59 million for the nine months ended January 31, 2025.

Q3 FY2025 GAAP oncology revenue reached $17.04 million, up from $12.02 million in Q3 FY2024.

Net income of $6.54 million for nine months ended January 31, 2025.

Cash and equivalents totaled $3.20 million at Q3 FY2025.

Bottom Line

Champions Oncology is a technology-driven research organization specializing in drug discovery and development. The company's integrated platforms combine computational and experimental approaches to advance therapeutic solutions.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

214

CEO

Robert Brainin

Website

www.championsoncology.com

Headquarters

Hackensack, NJ 07601, US

CSBR Financials

Key Financial Metrics (TTM)

Gross Margin

48.00%

Operating Margin

-1.92%

Net Income Margin

-1.98%

Return on Equity

-29.56%

Return on Capital

-13.36%

Return on Assets

-4.35%

Earnings Yield

-1.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$74.47M

Shares Outstanding

13.89M

Volume

2.01K

Avg. Volume

9.21K

Financials (TTM)

Gross Profit

$28.53M

Operating Income

-$1.14M

EBITDA

$448.00K

Operating Cash Flow

-$4.47M

Capital Expenditure

-$564.00K

Free Cash Flow

-$5.04M

Cash & ST Invst.

$4.87M

Total Debt

$4.60M

Champions Oncology Performance Analysis

Champions Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-04-30	USD 53,870,000	9.7%
2024	2024-04-30	USD 50,155,000	-6.9%
2025	2025-04-30	USD 56,944,000	13.5%
2026	2026-04-30	USD 59,425,000	4.4%

Champions Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-07-31	13.3%
Q2	2025-10-31	7.4%
Q3	2026-01-31	10.1%
Q4	2026-04-30	-16.4%

Champions Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-04-30	USD -0.39	N/A
2024	2024-04-30	USD -0.54	36.3%
2025	2025-04-30	USD 0.33	N/A
2026	2026-04-30	USD -0.09	N/A

Champions Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-07-31	75.7%
Q2	2025-10-31	158.5%
Q3	2026-01-31	-208.1%
Q4	2026-04-30	-134.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

$13.84M

+12.0%

Gross Profit

$7.03M

+38.2%

Gross Margin

50.79%

N/A

Market Cap

$74.47M

N/A

Market Cap/Employee

$349.62K

N/A

Employees

213

N/A

Net Income

-$729.00K

+60.3%

EBITDA

-$174.00K

+88.9%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

$4.87M

-50.2%

Total Debt

$4.60M

-24.7%

Accounts Receivable

$13.18M

+17.3%

Inventory

$0.00

N/A

Long Term Debt

$3.00M

-35.3%

Short Term Debt

$1.60M

+8.7%

Return on Assets

-4.35%

N/A

Return on Invested Capital

-16.13%

N/A

Free Cash Flow

-$2.24M

-133.8%

Operating Cash Flow

-$2.00M

-129.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ATRAAtara Biotherapeutics, Inc.

ATRAAtara Biotherapeutics, Inc.$8.38+2.57%

KLRSKalaris Therapeutics Inc

KLRSKalaris Therapeutics Inc$3.51+0.86%

IMAImageneBio Inc

IMAImageneBio Inc$5.54-6.26%

MGXMetagenomi, Inc. Common Stock

MGXMetagenomi, Inc. Common Stock$1.19-2.46%

IFRXInflaRx N.V.

IFRXInflaRx N.V.$1.70-1.16%

CNTBConnect Biopharma Holdings Limited

CNTBConnect Biopharma Holdings Limited$2.02-3.35%

ORMPOramed Pharmaceuticals Inc.

ORMPOramed Pharmaceuticals Inc.$4.07-1.21%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About CSBR

What is the current price of Champions Oncology?

Champions Oncology is trading at $5.36 per share.

What is the 52-week range for Champions Oncology?

Over the past 52 weeks, Champions Oncology has traded between $5.22 and $8.74.

How much debt does Champions Oncology have?

As of the most recent reporting period, Champions Oncology reported total debt of $4.60M.

How much cash does Champions Oncology have on hand?

Champions Oncology reported $4.87M in cash and cash equivalents in its most recent financial results.

What is Champions Oncology’s dividend yield?

Champions Oncology does not currently have a dividend yield.

Champions Oncology(NASDAQ) CSBR

Champions Oncology Financials at a Glance

CSBR News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Champions Oncology

The Cancer-Fighting Toolkit

Evolution of a Cancer Tech Pioneer

What Sets Champions Apart

Financial Vital Signs

Bottom Line

CSBR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Champions Oncology Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CSBR

What is the current price of Champions Oncology?

What is the 52-week range for Champions Oncology?

How much debt does Champions Oncology have?

How much cash does Champions Oncology have on hand?

What is Champions Oncology’s dividend yield?

Premium Investing Services